Andreas Halvorsen

Viking Global

Andreas Halvorsen is a prominent figure in the investment management industry, serving as the co-founder and CEO of Viking Global Investors, an American hedge fund firm based in Stamford, Connecticut. The firm is known for its expertise in long-short equity, long-only equity, and private equity strategies. Halvorsen's investment philosophy emphasizes rigorous fundamental analysis and a focus on long-term value creation, which has positioned Viking Global as a significant player in the financial markets. Viking Global Investors employs a multi-strategy approach, leveraging its deep research capabilities to navigate various sectors, including healthcare, financial services, and consumer cyclical industries. The firm actively manages a diverse portfolio, which has included notable positions in companies such as Apple Inc., Microsoft Corp., and DraftKings Inc. Their strategy involves a combination of position increases, reductions, and exits, reflecting a dynamic approach to market opportunities. Recent disclosures from Viking Global indicate a range of activities between November 14, 2025, and May 15, 2026, with a total of 200 reported moves. The firm has shown a pattern of significant position reductions and exits, particularly highlighted by a notable move involving Microsoft Corp, which saw a value of approximately $1.3 billion. This activity underscores Halvorsen's adaptive investment strategy in response to market conditions.

Latest Holdings

HoldingReported ValueWeightSharesLast PriceEst. ValueReturn
Cboe Global Markets, Inc.CBOE · Q1 2026$193M0.5%688.4k$277.11$191M-1.41%
Roivant Sciences Ltd.ROIV · Q1 2026$184M0.5%6.7M$34.96$233M+26.2%
Home Depot, Inc. (The) Common StockHD · Q1 2026$166M0.5%504.3k$331.45$167M+0.78%
Arthur J. Gallagher & CoAJG · Q1 2026$158M0.4%727.4k$254.22$185M+17.4%
Lululemon Athletica Inc.LULU · Q1 2026$150M0.4%980.6k$117.42$115M-23.3%
N62509109N62509109 · Q1 2026$135M0.4%4.2M------
687604108687604108 · Q1 2026$131M0.4%2.7M------
Sionna Therapeutics, Inc.SION · Q1 2026$128M0.4%3.2M$45.29$145M+13%
Stellantis NVSTLA · Q1 2026$112M0.3%16M$5.90$94M-15.8%
CoreWeave, Inc. Class A Common StockCRWV · Q1 2026$108M0.3%1.4M$79.58$111M+2.72%
Veradermics, IncorporatedMANE · Q1 2026$107M0.3%1.7M$105.83$179M+67.6%
West Pharmaceutical Services, Inc.WST · Q1 2026$105M0.3%416.9k$359.00$150M+43.2%
Pharvaris N.V.PHVS · Q1 2026$103M0.3%3.7M$33.55$123M+18.8%
45720N10345720N103 · Q1 2026$97M0.3%1.4M------
Interactive Brokers Group, Inc.IBKR · Q1 2026$94M0.3%1.4M$93.29$130M+39.1%
Ralliant Corp.RAL · Q1 2026$89M0.2%2.1M$67.53$144M+62.4%
2.8176E+1122.8176E+112 · Q1 2026$88M0.2%1.1M------
ORIC Pharmaceuticals, Inc.ORIC · Q1 2026$74M0.2%5.8M$10.73$62M-15.3%
36322Q20636322Q206 · Q1 2026$60M0.2%2.3M------
Twilio Inc.TWLO · Q1 2026$57M0.2%450.8k$211.54$95M+68.1%
Standard BioTools Inc.LAB · Q1 2026$54M0.2%58.7M$0.8575$50M-6.72%
Trevi Therapeutics, Inc.TRVI · Q1 2026$38M0.1%3.2M$17.36$56M+45.5%
Ginkgo Bioworks Holdings, Inc.DNA · Q1 2026$22M0.1%3.6M$8.29$30M+35.2%
29445S10029445S100 · Q1 2026$20M0.1%1M------
34631F10234631F102 · Q1 2026$19M0.1%650k------
713317105713317105 · Q1 2026$6M0%3.5M------
75120L20975120L209 · Q1 2026$5M0%524.3k------
Showing 51-77 of 77